The MODY panel is a targeted genetic test that screens genes causing maturity‑onset diabetes of the young (MODY). It typically includes GCK, HNF1A, HNF4A, HNF1B and other MODY-associated genes. Results confirm diagnosis, clarify inheritance (usually autosomal dominant), predict prognosis and guide treatment choices (for example sulfonylureas versus insulin), and identify relatives for testing.

Maturity-onset diabetes of the young (MODY) is caused by single-gene mutations. The common genes are HNF1A, GCK, HNF4A and HNF1B. Less common MODY genes include PDX1 (IPF1), NEUROD1, KLF11, CEL, PAX4, INS, BLK, ABCC8, KCNJ11 and APPL1. Different mutations cause variable onset, features and treatment needs.

Genetic testing for MODY in India typically ranges from about ₹5,000–15,000 for single‑gene tests, ₹15,000–45,000 for multi‑gene MODY panels, and ₹40,000–100,000+ for broader options like whole‑exome sequencing. Costs vary by laboratory, number of genes tested, sequencing technology, and whether family testing or clinical interpretation is included; confirm exact pricing and turnaround with the chosen diagnostic lab.

The only definitive test for MODY is molecular genetic testing (targeted gene panel or sequencing for MODY genes such as HNF1A, HNF4A, GCK). Supportive tests include preserved C‑peptide, negative pancreatic autoantibodies (GAD/IA‑2) to exclude type 1 diabetes, HbA1c/fasting glucose, and family cascade testing. Genetic confirmation guides treatment and relatives’ testing.

A gene panel test examines many genes at once to find DNA changes linked to a specific condition or group of disorders (for example hereditary cancers, heart, or neurological diseases). Using sequencing or targeted mutation analysis, it can confirm diagnoses, estimate risk, guide treatment, and inform family testing. Results may be positive, negative, or variants of uncertain significance. Genetic counseling is recommended before and after testing.

C-peptide is not typically high in MODY. Levels are usually normal or relatively preserved early on, but can be low in progressive β‑cell–deficient subtypes (e.g., HNF1A, HNF4A) or with longer disease duration. GCK‑MODY generally shows near‑normal C‑peptide. C‑peptide testing helps distinguish MODY from type 1 or advanced type 2 diabetes but needs clinical and genetic correlation.